Bodypharm CJC 1295 with DAC 2 Vial

Body Pharm CJC-1295 with DAC 2mg is a lyophilised research peptide vial for in vitro investigation of GHRH analogue activity. The DAC (Drug Affinity Complex) modification extends the half-life to a commonly cited 6–8 days versus a sub-30-minute window for the non-DAC variant. This happens because the maleimidopropionic acid linker binds covalently to circulating serum albumin and protects the peptide from enzymatic cleavage. The live ZAR price is shown in the buy box at the top of this page.

Key Takeaways

• CJC-1295 with DAC extends half-life to ~6–8 days through covalent albumin binding, versus sub-30 minutes for non-DAC variants
• The 6–8 day figure originates from Teichman et al. (2006); no newer primary pharmacokinetic data has been published
• Body Pharm supplies the peptide as a 2 mg lyophilised vial
• Request a batch-specific Certificate of Analysis before use; purity specifications are not independently verifiable from available sources
• Storage requires 2–8 °C protection from light; cold-chain handling during South African summer delivery is critical

What Is Body Pharm CJC-1295 with DAC 2mg?

Body Pharm CJC-1295 with DAC 2mg is a synthetic 30-amino-acid GHRH analogue (DAC:GRF) supplied as a 2 mg lyophilised powder for in vitro laboratory research. The Drug Affinity Complex (DAC) is a maleimidopropionic acid linker that binds covalently to circulating serum albumin, protecting the peptide from dipeptidyl peptidase-IV cleavage and extending the cited half-life to roughly 6–8 days. The non-DAC modified GRF (1-29) form clears within sub-30 minutes.

ConjuChem developed the DAC conjugation chemistry in the early 2000s. Teichman et al. (2006) characterised the resulting long-acting GHRH activity in the pharmacokinetic work that the 6–8 day figure traces back to. No post-2006 primary PK replication was located in the current source set. The half-life value should be treated as 2006-era data pending newer literature.

Body Pharm distributes the peptide in a single-vial 2 mg format. A manufacturer Certificate of Analysis and stated purity specification could not be verified from the available sources. Request these documents from the seller before order release.

Quick product definition

CJC-1295 with DAC vs. Without DAC

The core procurement decision comes down to dosing cadence. DAC binds covalently to serum albumin and extends activity to roughly 6–8 days. The non-DAC Modified GRF (1-29) form clears within minutes and requires multiple administrations per research day because it lacks the albumin-binding modification.